The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 04, 2023

Filed:

Jul. 21, 2022
Applicant:

Purecodon (Hong Kong) Biopharma Ltd., Hong Kong, CN;

Inventors:

Ke Huang, Suzhou, CN;

Binxi Ge, Suzhou, CN;

Yingwen Li, Suzhou, CN;

Yuping Liu, Suzhou, CN;

Yinjia Gao, Suzhou, CN;

Zhenhua Sun, Suzhou, CN;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); A61K 47/10 (2017.01); A61K 31/713 (2006.01); A61K 9/127 (2006.01); A61K 9/14 (2006.01); C07C 217/08 (2006.01); C07C 219/06 (2006.01); C07C 229/16 (2006.01); C07C 233/18 (2006.01); C07C 233/36 (2006.01); C07C 237/12 (2006.01); C07C 323/25 (2006.01); C07C 323/52 (2006.01); A61K 47/18 (2017.01);
U.S. Cl.
CPC ...
A61K 48/005 (2013.01); A61K 9/127 (2013.01); A61K 9/145 (2013.01); A61K 31/713 (2013.01); A61K 47/10 (2013.01); A61K 47/18 (2013.01); A61K 48/0033 (2013.01); C07C 217/08 (2013.01); C07C 219/06 (2013.01); C07C 229/16 (2013.01); C07C 233/18 (2013.01); C07C 233/36 (2013.01); C07C 237/12 (2013.01); C07C 323/25 (2013.01); C07C 323/52 (2013.01);
Abstract

The present invention belongs to the technical field of gene therapy, and particularly relates to a series of lipid compounds as well as a lipid carrier, nucleic acid lipid nanoparticle composition and pharmaceutical preparation containing the same. A compound having a structure of a formula (I) provided by the present invention can be used for preparing a lipid carrier together with other lipid compounds, and exhibits pH response, and the entrapment efficiency to a nucleic acid drug is high, which greatly improves in-vivo delivery efficiency of the nucleic acid drug; and furthermore, a lipid compound with a specific structure can be chosen as a lipid carrier based on an organ in which the nucleic acid drug needs to be enriched, having a good market application prospect.


Find Patent Forward Citations

Loading…